ChromoCure (Genome Research Group) Announces Expanded White Paper: Collaboration Creates Authoritative Report on Aneuploidy Theo
04 Junho 2010 - 2:40PM
Marketwired
ChromoCure, Inc. (Genome Research Group, Inc. (GRG)) (PINKSHEETS:
KKUR) announced today the imminent publication of an expanded White
Paper on the Aneuploidy/ Chromosomal Theory of Cancer and its
groundbreaking Cancer Detection, Therapy and Cure technologies.
This authoritative paper will integrate the combined
Intellectual Property assets and of ChromoCure and GRG,
including:
- ChromoCure's advanced ChromoCure ChromoSomal CS200 and CS300
detection technology
- Fully automated cell sample preparation cycling, automated
multi-patient, multi-sample cell application to slide matrix
array
- On-Slide direct application of DNA-probes using robotic
micro-application, and user-selectable chromosome probe types;
single or multiple simultaneous probes
Full integration of de-paraffinization and cellular
disaggregation of tissue samples for non-cytology originated
diagnosticsGRG's full line of therapeutic protocols and
technology:
- Advanced therapeutic modeling protocols and algorithms
utilizing hypothermic modulation and resonance that allow for the
first time real-time progression monitoring and remission
detection
- GRG's therapeutic results and findings, methodologies and
proprietary knowledge in the non-toxic and non-invasive treatment
of cancer
- Real-time progression monitoring and remission detection
Protocols for chromosomal imbalance that include:
- Full scan of all chromosomes types within the cell population
sample, allowing for comprehensive DNA-index quantification and
precise measurement of imbalance ratios and amounts
- Increased data on cancer progression analysis
- Precise assessment of remission rates and protocol
efficacy
In announcing the release of this latest White Paper, ChromoCure
(GRG) leverages its recently announced merger to further establish
the Company's leading role in the new era of cancer detection, and
therapy, and cure.
The Company's cancer detection technology is based on the
chromosomal theory of cancer. Research has conclusively and
irrefutably demonstrated aneuploidy a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today.
This announcement adds further impetus to the worldwide increase
in medical genome research that has emerged since The Mayo Clinic
published its landmark findings confirming aneuploidy as the cause
of cancer in the December 2009 Cancer Cell journal. This
publication has spurred increased worldwide research by a number of
respected research universities and institutions, all of which have
published similar reports in 2010, and is cited to be one of the
contributing factors behind Walgreens' recently announced mail-in
genetic testing kits to be offered at 7,500 of their retail
locations nationwide.
The Company's combined technologies have been validated in
clinical trials and provide the foundation for significant advances
in diagnosis, therapy and cure, and placed the Company at the
forefront of both cancer detection and research. Shareholders can
expect further updates on research and testing collaborations,
laboratory partnerships, and research initiatives.
Management believes these initiatives to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation.
About Genome Research Group, Inc. (ChromoCure,
Inc.)
The Company develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has a proven
and effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research.
The Company owns proprietary cancer detection systems and
related therapeutic technologies and proprietary techniques for
non-toxic and non-invasive cancer therapy utilizing hypothermic
modulation and resonance. The Company's proprietary CS200
Chromosomal Scanner has been proven accurate and efficient in the
measurement of the unique genomic characteristic found in 100% of
all cancers and never found in normal cells. The Company's
detection technology has an effective accuracy of 100% for all
cancers at all stages. GRG's advanced Therapeutic Modeling and
Treatment Protocols, combined with its industry and medical
research collaborations, validate its leadership role in Cancer
Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that are forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated on the Company's website "investors"
section by reference) and should be read before any investment
decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Chromocure (CE) (USOTC:KKUR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024